Bridge Biotherapeutics Statistics

Total Valuation

Bridge Biotherapeutics has a market cap or net worth of KRW 170.61 billion. The enterprise value is 150.64 billion.

Market Cap	170.61B
Enterprise Value	150.64B

Important Dates

The next estimated earnings date is Monday, March 17, 2025.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Bridge Biotherapeutics has 43.30 million shares outstanding. The number of shares has increased by 10.79% in one year.

Current Share Class	n/a
Shares Outstanding	43.30M
Shares Change (YoY)	+10.79%
Shares Change (QoQ)	+3.54%
Owned by Insiders (%)	12.43%
Owned by Institutions (%)	9.65%
Float	37.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	6.86
P/TBV Ratio	8.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.06
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.29

Financial Position

The company has a current ratio of 4.56, with a Debt / Equity ratio of 0.10.

Current Ratio	4.56
Quick Ratio	4.37
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	-157.79

Financial Efficiency

Return on equity (ROE) is -96.83% and return on invested capital (ROIC) is -50.28%.

Return on Equity (ROE)	-96.83%
Return on Assets (ROA)	-42.41%
Return on Capital (ROIC)	-50.28%
Revenue Per Employee	30,857
Profits Per Employee	-850.47M
Employee Count	35
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +72.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+72.16%
50-Day Moving Average	3,926.90
200-Day Moving Average	3,109.28
Relative Strength Index (RSI)	54.38
Average Volume (20 Days)	1,735,024

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bridge Biotherapeutics had revenue of KRW 1.08 million and -29.77 billion in losses. Loss per share was -961.46.

Revenue	1.08M
Gross Profit	-15.26M
Operating Income	-26.93B
Pretax Income	-29.94B
Net Income	-29.77B
EBITDA	-25.49B
EBIT	-26.93B
Loss Per Share	-961.46

Full Income Statement

Balance Sheet

The company has 25.62 billion in cash and 2.80 billion in debt, giving a net cash position of 22.82 billion or 526.99 per share.

Cash & Cash Equivalents	25.62B
Total Debt	2.80B
Net Cash	22.82B
Net Cash Per Share	526.99
Equity (Book Value)	29.44B
Book Value Per Share	574.11
Working Capital	21.07B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.94 billion and capital expenditures -1.99 million, giving a free cash flow of -23.94 billion.

Operating Cash Flow	-23.94B
Capital Expenditures	-1.99M
Free Cash Flow	-23.94B
FCF Per Share	-552.94

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-2,493,215.46%
Pretax Margin	-2,772,121.91%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Bridge Biotherapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.79%
Shareholder Yield	-10.79%
Earnings Yield	-24.40%
FCF Yield	-14.03%

Stock Splits

The last stock split was on July 29, 2024. It was a forward split with a ratio of 1.2.

Last Split Date	Jul 29, 2024
Split Type	Forward
Split Ratio	1.2

Scores

Bridge Biotherapeutics has an Altman Z-Score of -1.14. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.14
Piotroski F-Score	n/a